Alzamend Neuro Regains Nasdaq Compliance

Alzamend Neuro, Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a notification letter from Nasdaq on September 14, 2026. The company demonstrated stockholders' equity of $5,802,680, exceeding the required minimum of $2.5 million, as reported in its Quarterly Report for the quarter ended July 31, 2026. Nasdaq confirmed that the compliance issue is now resolved.